Narrow your search
Listing 1 - 7 of 7
Sort by

Book
Interleukin-33 Biology in Tissue Development, Homeostasis and Disease
Authors: --- --- ---
Year: 2020 Publisher: Frontiers Media SA

Loading...
Export citation

Choose an application

Bookmark

Abstract

This eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact


Book
Interleukin-33 Biology in Tissue Development, Homeostasis and Disease
Authors: --- --- ---
Year: 2020 Publisher: Frontiers Media SA

Loading...
Export citation

Choose an application

Bookmark

Abstract

This eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact


Book
Interleukin-33 Biology in Tissue Development, Homeostasis and Disease
Authors: --- --- ---
Year: 2020 Publisher: Frontiers Media SA

Loading...
Export citation

Choose an application

Bookmark

Abstract

This eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact


Dissertation
Thesis, COLLÉGIALITÉ
Authors: --- --- --- ---
Year: 2022 Publisher: Liège Université de Liège (ULiège)

Loading...
Export citation

Choose an application

Bookmark

Abstract

Eosinophils are polymorphonuclear leukocytes mainly known for their role in protection against helminthic parasites. Beyond this immune function, eosinophils have been attributed diverse roles in health and disease. On the one hand, eosinophils contribute to immune and metabolic homeostasis and participate in tissue morphogenesis and regeneration. On the other hand, eosinophils are associated with tissue lesions in a variety of human diseases such as eosinophilic asthma, in which they are thought to play a pathogenic role. Indeed, the severity of eosinophilic asthma is positively correlated with the number of blood and tissue-infiltrating eosinophils, and biological therapies that eliminate or control the number of eosinophils improve control over exacerbations of severe forms of the disease. Nonetheless, mere counting of eosinophils is not a perfect predictor of the response of individual patients to anti-eosinophil targeted therapies. This led clinicians to posit that yet-to-identify factors may determine whether eosinophils are “good”, “bad” or “bystander” cells in asthma. Indeed, eosinophils are more labile than their classical vision as terminally differentiated effector cells posits. Eosinophils are able to adapt to their tissue microenvironment, which calls in the notion of plasticity.
In this work, we address the question of whether and how the alarmin interleukin (IL)-33, a pro-inflammatory cytokine of the IL-1 family and major activator of eosinophils, could participate in the plasticity of eosinophils. Indeed, it has been shown that IL-33 induces a plastic response in macrophages, in which it first elicits a pro-inflammatory gene expression program and later reprograms macrophages into pro-resolving and pro-remodeling cells. Therefore, we studied the short- and long-term transcriptomic response of human blood eosinophils to IL-33 ex vivo. The results showed that IL-33 induced a short term, NF-κB-controlled pro-inflammatory program in eosinophils but no detectable long-term transcriptomic response. Thus, our results suggest that IL-33 signaling does not elicit a long-term plastic response in eosinophils.


Book
Recent Advances in Antibody Therapeutics
Author:
Year: 2022 Publisher: Basel MDPI - Multidisciplinary Digital Publishing Institute

Loading...
Export citation

Choose an application

Bookmark

Abstract

Since first receiving approval in 1986, antibody-based therapeutics have been the most successful modality for the treatment of various diseases. This Special Issue of IJMS, “Recent Advances in Antibody Therapeutics”, presents leading-edge articles and reviews for discovery, development, and clinical applications of therapeutic antibodies, covering antibody drug conjugates (ADCs), GPCR-targeting antibodies, a functional antibody screening, bioassay of bispecific antibodies, antibody applications for cardiovascular diseases, antibody delivery to CNS, etc. The excellent studies in this Special Issue would valuable insight for scientists and clinicians in the field of therapeutic antibodies

Keywords

Research & information: general --- Chemistry --- interleukin 33 --- ST2 receptor --- scFv --- C2_2E12 --- bladder cancer --- antibodies --- immune checkpoint inhibitors --- antibody-drug conjugates --- sacituzumab govitecan --- enfortumab vedotin --- erdafitinib --- cost-effectiveness --- G protein-coupled receptor --- membrane protein --- antigen --- therapeutic antibody --- anti-angiogenesis --- delta-like ligand --- irinotecan --- paclitaxel --- VEGF --- SARS-CoV-2 --- spike protein --- receptor-binding domain --- phage display --- monoclonal antibody --- cytomegalovirus --- peptide/major histocompatibility complex class I complex --- T-cell-receptor-like antibody --- affinity maturation --- yeast surface display --- combinatorial antibody library --- agonist antibody --- cell fate --- bispecific antibodies --- bioassays --- mechanisms of action --- binding assays --- potency assays --- atherosclerosis --- inflammation --- antibody therapy --- blood–brain barrier --- antibody --- pharmacokinetics --- disposition --- biochemical and physicochemical properties --- Fc binding --- receptor-mediated transcytosis --- brain shuttle --- molecular Trojan horse --- transferrin --- anti-cancer antibody --- antibody engineering --- biophysical properties --- computational methods --- research cell bank --- antibody therapeutics --- recombinant antibodies --- intracellular antibodies --- single-chain antibody fragment --- nanobody --- Human papillomaviruses --- HPV oncoproteins --- HPV-associated cancer --- HPV cancer therapy --- asthma --- refractory asthma --- biomarker --- n/a --- blood-brain barrier


Book
Recent Advances in Antibody Therapeutics
Author:
Year: 2022 Publisher: Basel MDPI - Multidisciplinary Digital Publishing Institute

Loading...
Export citation

Choose an application

Bookmark

Abstract

Since first receiving approval in 1986, antibody-based therapeutics have been the most successful modality for the treatment of various diseases. This Special Issue of IJMS, “Recent Advances in Antibody Therapeutics”, presents leading-edge articles and reviews for discovery, development, and clinical applications of therapeutic antibodies, covering antibody drug conjugates (ADCs), GPCR-targeting antibodies, a functional antibody screening, bioassay of bispecific antibodies, antibody applications for cardiovascular diseases, antibody delivery to CNS, etc. The excellent studies in this Special Issue would valuable insight for scientists and clinicians in the field of therapeutic antibodies

Keywords

interleukin 33 --- ST2 receptor --- scFv --- C2_2E12 --- bladder cancer --- antibodies --- immune checkpoint inhibitors --- antibody-drug conjugates --- sacituzumab govitecan --- enfortumab vedotin --- erdafitinib --- cost-effectiveness --- G protein-coupled receptor --- membrane protein --- antigen --- therapeutic antibody --- anti-angiogenesis --- delta-like ligand --- irinotecan --- paclitaxel --- VEGF --- SARS-CoV-2 --- spike protein --- receptor-binding domain --- phage display --- monoclonal antibody --- cytomegalovirus --- peptide/major histocompatibility complex class I complex --- T-cell-receptor-like antibody --- affinity maturation --- yeast surface display --- combinatorial antibody library --- agonist antibody --- cell fate --- bispecific antibodies --- bioassays --- mechanisms of action --- binding assays --- potency assays --- atherosclerosis --- inflammation --- antibody therapy --- blood–brain barrier --- antibody --- pharmacokinetics --- disposition --- biochemical and physicochemical properties --- Fc binding --- receptor-mediated transcytosis --- brain shuttle --- molecular Trojan horse --- transferrin --- anti-cancer antibody --- antibody engineering --- biophysical properties --- computational methods --- research cell bank --- antibody therapeutics --- recombinant antibodies --- intracellular antibodies --- single-chain antibody fragment --- nanobody --- Human papillomaviruses --- HPV oncoproteins --- HPV-associated cancer --- HPV cancer therapy --- asthma --- refractory asthma --- biomarker --- n/a --- blood-brain barrier


Book
Recent Advances in Antibody Therapeutics
Author:
Year: 2022 Publisher: Basel MDPI - Multidisciplinary Digital Publishing Institute

Loading...
Export citation

Choose an application

Bookmark

Abstract

Since first receiving approval in 1986, antibody-based therapeutics have been the most successful modality for the treatment of various diseases. This Special Issue of IJMS, “Recent Advances in Antibody Therapeutics”, presents leading-edge articles and reviews for discovery, development, and clinical applications of therapeutic antibodies, covering antibody drug conjugates (ADCs), GPCR-targeting antibodies, a functional antibody screening, bioassay of bispecific antibodies, antibody applications for cardiovascular diseases, antibody delivery to CNS, etc. The excellent studies in this Special Issue would valuable insight for scientists and clinicians in the field of therapeutic antibodies

Keywords

Research & information: general --- Chemistry --- interleukin 33 --- ST2 receptor --- scFv --- C2_2E12 --- bladder cancer --- antibodies --- immune checkpoint inhibitors --- antibody-drug conjugates --- sacituzumab govitecan --- enfortumab vedotin --- erdafitinib --- cost-effectiveness --- G protein-coupled receptor --- membrane protein --- antigen --- therapeutic antibody --- anti-angiogenesis --- delta-like ligand --- irinotecan --- paclitaxel --- VEGF --- SARS-CoV-2 --- spike protein --- receptor-binding domain --- phage display --- monoclonal antibody --- cytomegalovirus --- peptide/major histocompatibility complex class I complex --- T-cell-receptor-like antibody --- affinity maturation --- yeast surface display --- combinatorial antibody library --- agonist antibody --- cell fate --- bispecific antibodies --- bioassays --- mechanisms of action --- binding assays --- potency assays --- atherosclerosis --- inflammation --- antibody therapy --- blood-brain barrier --- antibody --- pharmacokinetics --- disposition --- biochemical and physicochemical properties --- Fc binding --- receptor-mediated transcytosis --- brain shuttle --- molecular Trojan horse --- transferrin --- anti-cancer antibody --- antibody engineering --- biophysical properties --- computational methods --- research cell bank --- antibody therapeutics --- recombinant antibodies --- intracellular antibodies --- single-chain antibody fragment --- nanobody --- Human papillomaviruses --- HPV oncoproteins --- HPV-associated cancer --- HPV cancer therapy --- asthma --- refractory asthma --- biomarker

Listing 1 - 7 of 7
Sort by